<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548292" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548292/" /><meta name="ncbi_pagename" content="Clindamycin - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Clindamycin - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Clindamycin" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2019/12/16" /><meta name="citation_pmid" content="31643615" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548292/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Clindamycin" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2019/12/16" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548292/" /><meta name="description" content="Clindamycin is a broad spectrum antibiotic used orally, topically and parenterally for bacterial infections due to sensitive organisms. Clindamycin has been linked to rare instances of acute liver injury." /><meta name="og:title" content="Clindamycin" /><meta name="og:type" content="book" /><meta name="og:description" content="Clindamycin is a broad spectrum antibiotic used orally, topically and parenterally for bacterial infections due to sensitive organisms. Clindamycin has been linked to rare instances of acute liver injury." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548292/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Clindamycin/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548292/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8D132404663D910000000005DD01B8.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548292_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548292_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Clemastine/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Clobazam/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548292_"><span class="title" itemprop="name">Clindamycin</span></h1><p class="small">Last Update: <span itemprop="dateModified">December 16, 2019</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Clindamycin.OVERVIEW"><h2 id="_Clindamycin_OVERVIEW_">OVERVIEW</h2><div id="Clindamycin.Introduction"><h3>Introduction</h3><p>Clindamycin is a broad spectrum antibiotic used orally, topically and parenterally for bacterial infections due to sensitive organisms. Clindamycin has been linked to rare instances of acute liver injury.</p></div><div id="Clindamycin.Background"><h3>Background</h3><p>Clindamycin (klin" da mye' sin) is a lincomycin derivative with activity against many aerobic gram-positive cocci as well as many anaerobic gram-negative and gram-positive organisms. It has special activity against Bacteroides fragilis and some activity against Toxoplasma gondii and Pneumocystis jiroveci. Clindamycin acts by its binding to the 50S ribosomal subunit of bacteria, thus inhibiting protein synthesis. Clindamycin was approved for use in the United States in 1970 and is still in wide use with several million prescriptions being filled yearly. Current indications include moderate-to-severe bacterial infections caused by sensitive organisms. It is also used topically for acne and bacterial vaginosis. Clindamycin is available generically in oral and parenteral forms and as gels, foam, lotion and creams for topical use. Oral formulations include capsules of 75, 150 and 300 mg that are available in generic forms and under the commercial name of Cleocin. Clindamycin is also available in suspension for pediatric use. The typical adult dose is 600 to 2700 mg im or iv daily (in two divided doses) or 150 to 450 mg orally every 6 hours for 5 to 14 days, depending upon the type and severity of infection. Common side effects include nausea, diarrhea, headache and skin rash.</p></div><div id="Clindamycin.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Clindamycin has been linked to two forms of hepatotoxicity: transient serum aminotransferase elevations usually occurring after several days of high intravenous doses; and, an acute, idiosyncratic liver injury that arises within 1 to 3 weeks of starting therapy and is typically mild and self-limited.</p><p>High doses of intravenous clindamycin can be accompanied by elevations in serum <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> levels in the range of 2 to 10 times the upper limit of normal starting after 5 to 15 days of therapy in a manner similar to what occurs with intravenous oxacillin therapy (Case 1). Symptoms, jaundice, and alkaline phosphatase elevations are mild if they occur at all (Case 2), and aminotransferase levels rapidly fall into the normal range (in 1 to 2 weeks) upon stopping clindamycin or switching to lower doses or to oral formulations with which it rarely occurs.</p><p>Clindamycin therapy has also been linked to a clinically apparent, idiosyncratic liver injury that arises between 1 to 3 weeks after starting either oral or parenteral therapy (Case 3). The pattern of serum enzyme elevations is typically hepatocellular or mixed, but can be cholestatic. Allergic manifestations such as rash, fever and eosinophilia are typical, but often are not prominent and are not present in all cases. <a class="def" href="/books/n/livertox/glossary/def-item/glossary.autoantibodies/">Autoantibodies</a> are generally not present. The acute liver injury may accompany other signs of hypersensitivity such as Stevens Johnson syndrome or other severe skin reactions. The liver injury is usually mild-to-moderate in severity and resolves rapidly with stopping. However, fatal instances have been reported.</p><p>Likelihood score: B (highly likely cause of clinically apparent liver injury).</p></div><div id="Clindamycin.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The cause of <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> elevations during high dose clindamycin therapy is not known, but may be due to a direct but mild injury to the liver. Liver biopsy during these episodes generally shows minimal cell injury. The idiosyncratic reaction to clindamycin resembles the immunoallergic types of hepatitis that occur after many types of antibiotics, including the penicillins and cephalosporins.</p></div><div id="Clindamycin.Outcome_and_Management"><h3>Outcome and Management</h3><p>The serum aminotransferase elevations that appear during high dose intravenous therapy with clindamycin are usually benign, minimally symptomatic and resolve rapidly with stopping therapy or switching to oral forms of clindamycin. Acute idiosyncratic hepatitis can occur with either the parenteral or oral forms of clindamycin, but is rare. The liver injury can be symptomatic and prolonged and has been linked to one case of vanishing bile duct syndrome, but not with acute liver failure. Ordinarily, recovery can be expected in 4 to 8 weeks. Prednisone is not recommended. Patients should be told to avoid reexposure to clindamycin and other lincomycin derivatives.</p><p>Drug Class: <a href="/books/n/livertox/Antiinfective/">Antiinfective Agents</a></p></div></div><div id="Clindamycin.CASE_REPORTS"><h2 id="_Clindamycin_CASE_REPORTS_">CASE REPORTS</h2><div id="Clindamycin.Case_1_Serum_aminotransferas"><h3>Case 1. Serum aminotransferase elevations during intravenous therapy with clindamycin.(<a class="bk_pop" href="#Clindamycin.REF.1">1</a>)</h3><p>A 57 year old man with rheumatic heart disease and Staphylococcal endocarditis was treated with clindamycin (300 mg intravenously every 8 hours) and developed elevations in serum aminotransferase levels starting during the first week of therapy. Clindamycin was stopped at day 16 because of continuing elevations in <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> levels, which promptly began to fall when he was switched to cephalothin (Table). While blood cultures became negative on therapy, he subsequently died of E. coli sepsis.</p><div id="Clindamycin.Key_Points"><h4>Key Points</h4><div id="Clindamycin.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548292/table/Clindamycin.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Clindamycin.Tc_lrgtbl__"><table><tbody><tr><th id="hd_b_Clindamycin.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medication:</th><td headers="hd_b_Clindamycin.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Clindamycin, 300 mg IV every 8 hours</td></tr><tr><th id="hd_b_Clindamycin.Tc_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pattern:</th><td headers="hd_b_Clindamycin.Tc_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Probably hepatocellular</td></tr><tr><th id="hd_b_Clindamycin.Tc_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Severity:</th><td headers="hd_b_Clindamycin.Tc_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1+ (no jaundice)</td></tr><tr><th id="hd_b_Clindamycin.Tc_1_1_4_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</th><td headers="hd_b_Clindamycin.Tc_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 days to <a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a> elevations</td></tr><tr><th id="hd_b_Clindamycin.Tc_1_1_5_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Recovery:</th><td headers="hd_b_Clindamycin.Tc_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incomplete</td></tr><tr><th id="hd_b_Clindamycin.Tc_1_1_6_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other medications:</th><td headers="hd_b_Clindamycin.Tc_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None mentioned</td></tr></tbody></table></div></div></div><div id="Clindamycin.Laboratory_Values"><h4>Laboratory Values</h4><div id="Clindamycin.Td" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548292/table/Clindamycin.Td/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Clindamycin.Td_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_Clindamycin.Td_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Days After Starting</th><th id="hd_h_Clindamycin.Td_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Days After Stopping</th><th id="hd_h_Clindamycin.Td_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a><br /> (U/L)</th><th id="hd_h_Clindamycin.Td_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a><br /> (U/L)</th><th id="hd_h_Clindamycin.Td_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">LDH<br /> (U/L)</th><th id="hd_h_Clindamycin.Td_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Clindamycin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Pre</td><td headers="hd_h_Clindamycin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">10</td><td headers="hd_h_Clindamycin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">700</td><td headers="hd_h_Clindamycin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Clindamycin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0</td><td headers="hd_h_Clindamycin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Td_1_1_1_3 hd_h_Clindamycin.Td_1_1_1_4 hd_h_Clindamycin.Td_1_1_1_5 hd_h_Clindamycin.Td_1_1_1_6" colspan="4" rowspan="1" style="text-align:center;vertical-align:top;">Clindamycin started (300 mg IV q 8 hr)</td></tr><tr><td headers="hd_h_Clindamycin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">5</td><td headers="hd_h_Clindamycin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">55</td><td headers="hd_h_Clindamycin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">70</td><td headers="hd_h_Clindamycin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1020</td><td headers="hd_h_Clindamycin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Clindamycin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">9</td><td headers="hd_h_Clindamycin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">310</td><td headers="hd_h_Clindamycin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">320</td><td headers="hd_h_Clindamycin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1400</td><td headers="hd_h_Clindamycin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Clindamycin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">16</td><td headers="hd_h_Clindamycin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">510</td><td headers="hd_h_Clindamycin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">600</td><td headers="hd_h_Clindamycin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2100</td><td headers="hd_h_Clindamycin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Clindamycin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0</td><td headers="hd_h_Clindamycin.Td_1_1_1_3 hd_h_Clindamycin.Td_1_1_1_4 hd_h_Clindamycin.Td_1_1_1_5 hd_h_Clindamycin.Td_1_1_1_6" colspan="4" rowspan="1" style="text-align:center;vertical-align:top;">Clindamycin stopped: cephalothin started</td></tr><tr><td headers="hd_h_Clindamycin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">24</td><td headers="hd_h_Clindamycin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">8</td><td headers="hd_h_Clindamycin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">230</td><td headers="hd_h_Clindamycin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">125</td><td headers="hd_h_Clindamycin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1420</td><td headers="hd_h_Clindamycin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Clindamycin.Td_1_1_1_1 hd_h_Clindamycin.Td_1_1_1_2" colspan="2" scope="row" rowspan="1" style="text-align:center;vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Clindamycin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;40</b></td><td headers="hd_h_Clindamycin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;40</b></td><td headers="hd_h_Clindamycin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>Not given</b></td><td headers="hd_h_Clindamycin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>*</dt><dd><div id="Clindamycin.TF.d.1"><p class="no_margin">Values estimated from Figure 1.</p></div></dd></dl></div></div></div></div><div id="Clindamycin.Comment"><h4>Comment</h4><p>A typical pattern of serum aminotransferase elevations during intravenous clindamycin therapy that can be seen with several antibiotics, most typically with oxacillin. The liver injury usually arises after 4 to 6 days and is minimally symptomatic, anicteric and resolves rapidly when the antibiotic is stopped. The injury is probably dose related and a direct toxic effect of clindamycin or oxacillin.</p></div></div><div id="Clindamycin.Case_2_Acute_hepatitis_arisi"><h3>Case 2. Acute hepatitis arising during intravenous therapy with clindamycin.(<a class="bk_pop" href="#Clindamycin.REF.2">2</a>)</h3><p>An 18 year old man with acute bacterial endocarditis related to injection drug use developed elevated serum aminotransferases and then jaundice during intravenous clindamycin therapy. The patient had been treated with high doses of cephalothin and vancomycin for over two months with an inadequate response, during which time his liver tests were normal. Blood cultures revealed Staphylococcus aureus sensitive to clindamycin, and he was started on intravenous clindamycin (3.6 g/day) with a rapid clinical improvement. After a week, however, serum <a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a> levels began to rise. The dose of clindamycin was cut in half, but he subsequently developed urticaria, recurrence of fever, jaundice and rising AST levels (Table). Tests for hepatitis B were negative, and liver biopsy showed acute hepatitis without fibrosis compatible with a drug induced liver injury. Clindamycin was stopped and the rash, fever and jaundice promptly resolved. Follow up blood cultures were negative and serum AST levels were normal when tested one month later.</p><div id="Clindamycin.Key_Points_1"><h4>Key Points</h4><div id="Clindamycin.Te" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548292/table/Clindamycin.Te/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Clindamycin.Te_lrgtbl__"><table><tbody><tr><th id="hd_b_Clindamycin.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medication:</th><td headers="hd_b_Clindamycin.Te_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Clindamycin, 3.6 g iv daily for 30 days</td></tr><tr><th id="hd_b_Clindamycin.Te_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pattern:</th><td headers="hd_b_Clindamycin.Te_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hepatocellular (R=9.1)</td></tr><tr><th id="hd_b_Clindamycin.Te_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Severity:</th><td headers="hd_b_Clindamycin.Te_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3+ (jaundiced and hospitalization prolonged)</td></tr><tr><th id="hd_b_Clindamycin.Te_1_1_4_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</th><td headers="hd_b_Clindamycin.Te_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8 days to <a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a> elevations, 22 days to jaundice</td></tr><tr><th id="hd_b_Clindamycin.Te_1_1_5_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Recovery:</th><td headers="hd_b_Clindamycin.Te_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Within one month</td></tr><tr><th id="hd_b_Clindamycin.Te_1_1_6_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other medications:</th><td headers="hd_b_Clindamycin.Te_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None mentioned</td></tr></tbody></table></div></div></div><div id="Clindamycin.Laboratory_Values_1"><h4>Laboratory Values</h4><div id="Clindamycin.Tf" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548292/table/Clindamycin.Tf/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Clindamycin.Tf_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_Clindamycin.Tf_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After Starting</th><th id="hd_h_Clindamycin.Tf_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After Stopping</th><th id="hd_h_Clindamycin.Tf_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a>*<br />(U/L)</th><th id="hd_h_Clindamycin.Tf_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Alk P*<br />(U/L)</th><th id="hd_h_Clindamycin.Tf_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a>*<br />(mg/dL)</th><th id="hd_h_Clindamycin.Tf_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Clindamycin.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Tf_1_1_1_3 hd_h_Clindamycin.Tf_1_1_1_4 hd_h_Clindamycin.Tf_1_1_1_5 hd_h_Clindamycin.Tf_1_1_1_6" colspan="4" rowspan="1" style="text-align:center;vertical-align:top;">Clindamycin (3.6 gm IV daily) started for endocarditis</td></tr><tr><td headers="hd_h_Clindamycin.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Pre</td><td headers="hd_h_Clindamycin.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">30</td><td headers="hd_h_Clindamycin.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">59</td><td headers="hd_h_Clindamycin.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.8</td><td headers="hd_h_Clindamycin.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Clindamycin.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">5 days</td><td headers="hd_h_Clindamycin.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">40</td><td headers="hd_h_Clindamycin.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Clindamycin.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">8 days</td><td headers="hd_h_Clindamycin.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">110</td><td headers="hd_h_Clindamycin.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Clindamycin.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">10 days</td><td headers="hd_h_Clindamycin.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">310</td><td headers="hd_h_Clindamycin.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Clindamycin.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">14 days</td><td headers="hd_h_Clindamycin.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">480</td><td headers="hd_h_Clindamycin.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.5</td><td headers="hd_h_Clindamycin.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Clindamycin.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">16 days</td><td headers="hd_h_Clindamycin.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">710</td><td headers="hd_h_Clindamycin.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Reduced dose</td></tr><tr><td headers="hd_h_Clindamycin.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3 weeks</td><td headers="hd_h_Clindamycin.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">750</td><td headers="hd_h_Clindamycin.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">80</td><td headers="hd_h_Clindamycin.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3.5</td><td headers="hd_h_Clindamycin.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Clindamycin.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4 weeks</td><td headers="hd_h_Clindamycin.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">80</td><td headers="hd_h_Clindamycin.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.8</td><td headers="hd_h_Clindamycin.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Liver biopsy</td></tr><tr><td headers="hd_h_Clindamycin.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Tf_1_1_1_3 hd_h_Clindamycin.Tf_1_1_1_4 hd_h_Clindamycin.Tf_1_1_1_5 hd_h_Clindamycin.Tf_1_1_1_6" colspan="4" rowspan="1" style="text-align:center;vertical-align:top;">Fever and urticaria: clindamycin stopped</td></tr><tr><td headers="hd_h_Clindamycin.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">5 weeks</td><td headers="hd_h_Clindamycin.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4 days</td><td headers="hd_h_Clindamycin.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">50</td><td headers="hd_h_Clindamycin.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Clindamycin.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">6 weeks</td><td headers="hd_h_Clindamycin.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">10 days</td><td headers="hd_h_Clindamycin.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">80</td><td headers="hd_h_Clindamycin.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.1</td><td headers="hd_h_Clindamycin.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Clindamycin.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">7 weeks</td><td headers="hd_h_Clindamycin.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">18 days</td><td headers="hd_h_Clindamycin.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">160</td><td headers="hd_h_Clindamycin.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Normal</td><td headers="hd_h_Clindamycin.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Clindamycin.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2 months</td><td headers="hd_h_Clindamycin.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1 month</td><td headers="hd_h_Clindamycin.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">30</td><td headers="hd_h_Clindamycin.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.9</td><td headers="hd_h_Clindamycin.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Clindamycin.Tf_1_1_1_1 hd_h_Clindamycin.Tf_1_1_1_2" colspan="2" scope="row" rowspan="1" style="text-align:center;vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Clindamycin.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;40</b></td><td headers="hd_h_Clindamycin.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;40</b></td><td headers="hd_h_Clindamycin.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_Clindamycin.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>*</dt><dd><div id="Clindamycin.TF.f.1"><p class="no_margin">Values estimated from Figure 1.</p></div></dd></dl></div></div></div></div><div id="Clindamycin.Comment_1"><h4>Comment</h4><p>A typical pattern of serum aminotransferase elevations arising after a week of intravenous clindamycin therapy. The clindamycin dose was decreased because of the rising <a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a> levels, but fever and urticaria arose, and clindamycin was stopped, whereupon the liver injury resolved rapidly. This example suggests that the asymptomatic elevations in serum aminotransferase levels during intravenous clindamycin therapy can evolve into the immunoallergic and icteric form of liver injury if therapy is continued. This report predated the availability of tests for hepatitis C, which may have been at least partially responsible for the liver injury in this patient.</p></div></div><div id="Clindamycin.Case_3_Acute_hepatitis_with"><h3>Case 3. Acute hepatitis with jaundice arising during clindamycin therapy.(<a class="bk_pop" href="#Clindamycin.REF.3">3</a>)</h3><p>A 42 year old woman developed fatigue, nausea, anorexia, pruritus and dark urine followed by jaundice 6 days after starting a course of clindamycin (150 mg four times a day) for a gingival infection. She had received clindamycin for this same problem several times in the past without complications. She had no history of liver disease, alcohol abuse or risk factors for viral hepatitis and was taking no other medications. On presentation, she was jaundiced but without rash or fever. Laboratory testing showed an <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> of 1795 U/L, <a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a> 1337 U/L, alkaline phosphatase 339 U/L, <a class="def" href="/books/n/livertox/glossary/def-item/glossary.gamma-glutamyl-transpeptidase-ggt-/">GGT</a> 148 U/L, total bilirubin 4.1 mg/dL (direct 2.9 mg/dL) and INR 1.04. The eosinophil count was normal. Tests for hepatitis A, B and C and for cytomegalovirus and Epstein Barr virus infection were negative. <a class="def" href="/books/n/livertox/glossary/def-item/glossary.autoantibodies/">Autoantibodies</a>, including ANA, SMA and anti-LKM, were negative and an abdominal ultrasound showed no evidence of biliary obstruction. A liver biopsy showed cholestatic hepatitis without fibrosis, suggestive of drug induced liver injury. After 3 weeks, she was largely asymptomatic and all liver tests had returned to normal when she was seen 8 weeks after presentation (Table).</p><div id="Clindamycin.Key_Points_2"><h4>Key Points</h4><div id="Clindamycin.Tg" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548292/table/Clindamycin.Tg/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Clindamycin.Tg_lrgtbl__"><table><tbody><tr><th id="hd_b_Clindamycin.Tg_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medication:</th><td headers="hd_b_Clindamycin.Tg_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Clindamycin, 150 mg 4 times daily</td></tr><tr><th id="hd_b_Clindamycin.Tg_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pattern:</th><td headers="hd_b_Clindamycin.Tg_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hepatocellular (R=44.9)</td></tr><tr><th id="hd_b_Clindamycin.Tg_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Severity:</th><td headers="hd_b_Clindamycin.Tg_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3+ (jaundiced and hospitalized)</td></tr><tr><th id="hd_b_Clindamycin.Tg_1_1_4_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</th><td headers="hd_b_Clindamycin.Tg_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 days to symptoms</td></tr><tr><th id="hd_b_Clindamycin.Tg_1_1_5_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Recovery:</th><td headers="hd_b_Clindamycin.Tg_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Within two months</td></tr><tr><th id="hd_b_Clindamycin.Tg_1_1_6_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other medications:</th><td headers="hd_b_Clindamycin.Tg_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td></tr></tbody></table></div></div></div><div id="Clindamycin.Laboratory_Values_2"><h4>Laboratory Values</h4><div id="Clindamycin.Th" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548292/table/Clindamycin.Th/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Clindamycin.Th_lrgtbl__"><table><thead><tr><th id="hd_h_Clindamycin.Th_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After Starting</th><th id="hd_h_Clindamycin.Th_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After Stopping</th><th id="hd_h_Clindamycin.Th_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a><br />(U/L)</th><th id="hd_h_Clindamycin.Th_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Alk P<br />(U/L)</th><th id="hd_h_Clindamycin.Th_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a><br />(mg/dL)</th><th id="hd_h_Clindamycin.Th_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Clindamycin.Th_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Th_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Th_1_1_1_3 hd_h_Clindamycin.Th_1_1_1_4 hd_h_Clindamycin.Th_1_1_1_5 hd_h_Clindamycin.Th_1_1_1_6" colspan="4" rowspan="1" style="text-align:center;vertical-align:top;">Clindamycin (150 mg qid) started for gingivitis</td></tr><tr><td headers="hd_h_Clindamycin.Th_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1 week</td><td headers="hd_h_Clindamycin.Th_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0</td><td headers="hd_h_Clindamycin.Th_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1795</td><td headers="hd_h_Clindamycin.Th_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">339</td><td headers="hd_h_Clindamycin.Th_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4.1</td><td headers="hd_h_Clindamycin.Th_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Admission</td></tr><tr><td headers="hd_h_Clindamycin.Th_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2 weeks</td><td headers="hd_h_Clindamycin.Th_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1 week</td><td headers="hd_h_Clindamycin.Th_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1579</td><td headers="hd_h_Clindamycin.Th_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">345</td><td headers="hd_h_Clindamycin.Th_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3.3</td><td headers="hd_h_Clindamycin.Th_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Liver biopsy</td></tr><tr><td headers="hd_h_Clindamycin.Th_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4 weeks</td><td headers="hd_h_Clindamycin.Th_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3 weeks</td><td headers="hd_h_Clindamycin.Th_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">754</td><td headers="hd_h_Clindamycin.Th_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">175</td><td headers="hd_h_Clindamycin.Th_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.8</td><td headers="hd_h_Clindamycin.Th_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Clindamycin.Th_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">9 weeks</td><td headers="hd_h_Clindamycin.Th_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">8 weeks</td><td headers="hd_h_Clindamycin.Th_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">28</td><td headers="hd_h_Clindamycin.Th_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Clindamycin.Th_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.7</td><td headers="hd_h_Clindamycin.Th_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Clindamycin.Th_1_1_1_1 hd_h_Clindamycin.Th_1_1_1_2" colspan="2" scope="row" rowspan="1" style="text-align:center;vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Clindamycin.Th_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;40</b></td><td headers="hd_h_Clindamycin.Th_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;150</b></td><td headers="hd_h_Clindamycin.Th_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_Clindamycin.Th_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div></div></div><div id="Clindamycin.Comment_2"><h4>Comment</h4><p>While referred to as &#x0201c;cholestatic&#x0201d; in the title of the publication, the clinical presentation was clearly hepatocellular and acute viral hepatitis-like arising after a week of clindamycin therapy. No other medications were being taken and other causes of liver injury were adequately excluded. The liver injury was clearly idiosyncratic and likely due to hypersensitivity, despite the absence of immunoallergic features (rash, fever and eosinophilia). Previous courses of clindamycin may have sensitized the patient to the antibiotic. Isolated instances of cross sensitivity have been reported between clindamycin and the penicillins and future use of related antibiotics should be done with care.</p></div></div></div><div id="Clindamycin.PRODUCT_INFORMATION"><h2 id="_Clindamycin_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Clindamycin &#x02013; Generic, Cleocin&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antiinfective Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Clindamycin" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Clindamycin.CHEMICAL_FORMULA_AND_STRUCTU"><h2 id="_Clindamycin_CHEMICAL_FORMULA_AND_STRUCTU_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Clindamycin.Ti" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548292/table/Clindamycin.Ti/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Clindamycin.Ti_lrgtbl__"><table><thead><tr><th id="hd_h_Clindamycin.Ti_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_Clindamycin.Ti_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NO</th><th id="hd_h_Clindamycin.Ti_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Clindamycin.Ti_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Clindamycin.Ti_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Clindamycin</td><td headers="hd_h_Clindamycin.Ti_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134992359" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">18323-44-9</a></td><td headers="hd_h_Clindamycin.Ti_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C18-H33-Cl-N2-O5-S</td><td headers="hd_h_Clindamycin.Ti_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134992359" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=134992359" alt="image 134992359 in the ncbi pubchem database" /></a></td></tr></tbody></table></div></div></div><div id="Clindamycin.CITED_REFERENCES"><h2 id="_Clindamycin_CITED_REFERENCES_">CITED REFERENCES</h2><dl class="temp-labeled-list"><dt>1.</dt><dd><div class="bk_ref" id="Clindamycin.REF.1">Modified from Case #3: Hinthorn DR, Baker LH, Romig DA, Voth DW, Liu C. Endocarditis treated with clindamycin: relapse and liver dysfunction. <span><span class="ref-journal">South Med J. </span>1977;<span class="ref-vol">70</span>:823–6.</span> [<a href="/pubmed/877644" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 877644</span></a>]</div></dd><dt>2.</dt><dd><div class="bk_ref" id="Clindamycin.REF.2">Elmore M, Rissing JP, Rink L, Brooks GF. Clindamycin-associated hepatotoxicity. <span><span class="ref-journal">Am J Med. </span>1974;<span class="ref-vol">57</span>:627–30.</span> [<a href="/pubmed/4432865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4432865</span></a>]</div></dd><dt>3.</dt><dd><div class="bk_ref" id="Clindamycin.REF.3">Aygun C, Kocaman O, Gurbuz Y, Senturk O, Hulagu S. Clindamycin-induced acute cholestatic hepatitis. <span><span class="ref-journal">World J Gastroenterol. </span>2007;<span class="ref-vol">13</span>:5408–10.</span> [<a href="/pmc/articles/PMC4171338/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4171338</span></a>] [<a href="/pubmed/17879418" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17879418</span></a>]</div></dd></dl></div><div id="Clindamycin.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Clindamycin_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 16 December 2019</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Clindamycin.REF.zimmerman.1999">Zimmerman HJ. Clindamycin. Hepatic injury from antimicrobial agents. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, p. 592.<div><i>(Expert review of liver injury published in 1999 mentions that ALT elevations are common during clindamycin therapy, and 2 cases of hepatocellular jaundice attributed to clindamycin have been published).</i></div></div></li><li><div class="bk_ref" id="Clindamycin.REF.moseley.2013">Moseley RH. Clindamycin. Hepatotoxicity of antimicrobials and antifungal agents. In, Kaplowitz N, DeLeve LD, eds. Drug-induced Liver Disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 470.<div><i>(Expert review of antibiotic induced liver injury mentions that clindamycin has been rarely reported to cause hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Clindamycin.REF.macdougall.2018">MacDougall C. Lincosamides (Clindamycin). Protein synthesis inhibitors and miscellaneous antibacterial agents. In, Brunton LL, Hillal-Dandan R, Knollman BA, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 1056-7.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Clindamycin.REF.elmore.1973.779">Elmore MF, Rink LD, Rissing JP. Clindamycin, endocarditis, hepatotoxicity. <span><span class="ref-journal">Ann Intern Med. </span>1973;<span class="ref-vol">78</span>:779–80.</span> [<a href="/pubmed/4711784" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4711784</span></a>]<div><i>(Letter to editor describing 18 year old injection drug user with acute bacterial endocarditis who developed marked AST elevation [710 U/L] after 18 days of iv clindamycin, resolving rapidly with stopping; 2 biopsies, first during therapy showed mild hepatitis, second during recovery showed resolution).</i></div></div></li><li><div class="bk_ref" id="Clindamycin.REF.fass.1973.853">Fass RJ, Scholand JF, Hodges GR, Saslaw S. Clindamycin in the treatment of serious anaerobic infections. <span><span class="ref-journal">Ann Intern Med. </span>1973;<span class="ref-vol">78</span>:853–9.</span> [<a href="/pubmed/4713566" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4713566</span></a>]<div><i>(Analysis of responses to parenteral clindamycin in 19 adults with serious infections, 8 of who developed mild, transient ALT and AST or Alk P elevations, but none required discontinuation or developed jaundice).</i></div></div></li><li><div class="bk_ref" id="Clindamycin.REF.craig.1974.43">Craig JA. Jaundice in acute pustular psoriasis. <span><span class="ref-journal">Br Med J. </span>1974;<span class="ref-vol">3</span>:43.</span> [<a href="/pmc/articles/PMC1611415/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1611415</span></a>] [<a href="/pubmed/4835475" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4835475</span></a>]<div><i>(62 year old woman developed jaundice 3 days after starting clindamycin therapy of sepsis [bilirubin 12.2 mg/dL, ALT normal]; likely due to sepsis rather than clindamycin).</i></div></div></li><li><div class="bk_ref" id="Clindamycin.REF.elmore.1974.627">Elmore M, Rissing JP, Rink L, Brooks GF. Clindamycin-associated hepatotoxicity. <span><span class="ref-journal">Am J Med. </span>1974;<span class="ref-vol">57</span>:627–30.</span> [<a href="/pubmed/4432865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4432865</span></a>]<div><i>(18 year old injection drug use with acute bacterial endocarditis developed jaundice [3.5 mg/dL] and AST elevations [710 U/L] after 21 days of iv clindamycin, resolving rapidly once therapy was stopped; two biopsies done, first during therapy showed mild hepatitis, second during recovery showed resolution: Case 2).</i></div></div></li><li><div class="bk_ref" id="Clindamycin.REF.levison.1974.276">Levison ME, Bran JL, Ries K. Treatment of anaerobic bacterial infections with clindamycin-2-phosphate. <span><span class="ref-journal">Antimicrob Agents Chemother. </span>1974;<span class="ref-vol">5</span>:276–80.</span> [<a href="/pmc/articles/PMC428960/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC428960</span></a>] [<a href="/pubmed/4600161" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4600161</span></a>]<div><i>(Among 35 patients treated with clindamycin im or iv for severe bacterial infections, mild elevations in ALT, AST and Alk P were common, one patient developed hepatitis 1 day after stopping 12 day course of clindamycin [bilirubin 5.6 mg/dL, ALT 680 U/L, Alk P 460 U/L], resolving within 3-4 months of stopping).</i></div></div></li><li><div class="bk_ref" id="Clindamycin.REF.williams.1975.153">Williams DN, Crossley K, Hoffman C, Sabath LD. Parenteral clindamycin phosphate: pharmacology with normal and abnormal liver function and effect on nasal staphylococci. <span><span class="ref-journal">Antimicrob Agents Chemother. </span>1975;<span class="ref-vol">7</span>:153–8.</span> [<a href="/pmc/articles/PMC429095/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC429095</span></a>] [<a href="/pubmed/1137366" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1137366</span></a>]<div><i>(Open label study of parenteral clindamycin therapy in 41 patients including 24 with preexisting liver disease; AST levels rose in 5 patients with liver disease and improved in others; among 17 patients without liver disease, AST levels rose in 4 [52, 57, 60 and 270 U/L], but elevations were self-limited and resolved spontaneously).</i></div></div></li><li><div class="bk_ref" id="Clindamycin.REF.hinthorn.1977.823">Hinthorn DR, Baker LH, Romig DA, Voth DW, Liu C. Endocarditis treated with clindamycin: relapse and liver dysfunction. <span><span class="ref-journal">South Med J. </span>1977;<span class="ref-vol">70</span>:823–6.</span> [<a href="/pubmed/877644" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 877644</span></a>]<div><i>(Among 6 patients treated for endocarditis with low rate of response, 2 developed ALT [~200 and 550 U/L], AST and LDH elevations after 8-18 days without jaundice or symptoms, resolving within 2 weeks of discontinuation: Case 1).</i></div></div></li><li><div class="bk_ref" id="Clindamycin.REF.kobayasi.1977.13">Kobayasi A, Sato S, Ito T, Utsumi T, Kikuchi N. <span><span class="ref-journal">Jpn J Antibiot. </span>1977;<span class="ref-vol">30</span>:13–21.</span> [Therapy for severe anaerobic infections with clindamycin (author's transl)] Japanese. [<a href="/pubmed/839638" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 839638</span></a>]<div><i>(From abstract: Among 11 patients given oral clindamycin for up to 49 days, one developed transient ALT elevations).</i></div></div></li><li><div class="bk_ref" id="Clindamycin.REF15">Prospective, randomized comparison of metronidazole and clindamycin, each with gentamicin, for the treatment of serious intra-abdominal infection. <span><span class="ref-journal">Surgery. </span>1983;<span class="ref-vol">93</span>(1 Pt 2):221–9.</span> [<a href="/pubmed/6849209" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6849209</span></a>]<div><i>(Multicenter study comparing clindamycin to metronidazole in 186 patients with severe infections; similar efficacy, AST elevations in 18% vs 10%, but no frank hepatitis or discontinuation for liver injury).</i></div></div></li><li><div class="bk_ref" id="Clindamycin.REF.altraif.1994.1230">Altraif I, Lilly L, Wanless IR, Heathcote J. Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and trimethoprim-sulfamethoxazole. <span><span class="ref-journal">Am J Gastroenterol. </span>1994;<span class="ref-vol">89</span>:1230–4.</span> [<a href="/pubmed/8053440" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8053440</span></a>]<div><i>(Two cases of vanishing bile duct syndrome, one due to clindamycin: a 67 year old man with jaundice arising 1 week after completion of a 10 day course [bilirubin 14.6 mg/dL, ALT 315 U/L, Alk P 271 U/L, GGT 468 U/L], followed by prolonged jaundice for 2-4 years [bilirubin 4.2 mg/dL, Alk P 179 U/L, ALT 67 U/L], liver biopsies showing progressive loss of bile ducts; ampicillin caused sudden worsening).</i></div></div></li><li><div class="bk_ref" id="Clindamycin.REF.maraqa.2002.50">Maraqa NF, Gomez MM, Rathore MH, Alvarez AM. Higher occurrence of hepatotoxicity and rash in patients treated with oxacillin, compared with those treated with nafcillin and other commonly used antimicrobials. <span><span class="ref-journal">Clin Infect Dis. </span>2002;<span class="ref-vol">34</span>:50–4.</span> [<a href="/pubmed/11731945" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11731945</span></a>]<div><i>(Retrospective review of 222 children receiving outpatient parenteral antibiotics; 22% receiving oxacillin, but only 1 of 72 receiving clindamycin developed &#x0201c;hepatitis&#x0201d; [at 17 days: bilirubin 0.6 mg/dL, ALT 183 U/L, AP normal]).</i></div></div></li><li><div class="bk_ref" id="Clindamycin.REF.de_valle.2006.1187">De Valle MB, Av Klinteberg V, Alem N, Olsson R, Bj&#x000f6;rnsson E. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. <span><span class="ref-journal">Aliment Pharmacol Ther. </span>2006;<span class="ref-vol">24</span>:1187–95.</span> [<a href="/pubmed/17014577" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17014577</span></a>]<div><i>(Survey of 77 cases of drug induced liver injury seen over 10 years, found 2 cases of clindamycin related injury, both hepatocellular, with onset after 7 and 35 days, resolution in 2 weeks and 6 months).</i></div></div></li><li><div class="bk_ref" id="Clindamycin.REF.aygun.2007.5408">Aygun C, Kocaman O, Gurbuz Y, Senturk O, Hulagu S. Clindamycin-induced acute cholestatic hepatitis. <span><span class="ref-journal">World J Gastroenterol. </span>2007;<span class="ref-vol">13</span>:5408–10.</span> [<a href="/pmc/articles/PMC4171338/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4171338</span></a>] [<a href="/pubmed/17879418" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17879418</span></a>]<div><i>(42 year old woman developed jaundice and pruritus after 6 days of oral clindamycin [bilirubin 4.1 mg/dL, ALT 1795 U/L, Alk P 339 U/L], resolving within 8 weeks of stopping).</i></div></div></li><li><div class="bk_ref" id="Clindamycin.REF.chalasani.2008.1924">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J., Drug Induced Liver Injury Network (DILIN).  Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. <span><span class="ref-journal">Gastroenterology. </span>2008;<span class="ref-vol">135</span>:1924–34.</span> [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="/pubmed/18955056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div><i>(Among 300 cases of drug induced liver disease in the US collected from 2004 to 2008, clindamycin was implicated in one case).</i></div></div></li><li><div class="bk_ref" id="Clindamycin.REF.flores_sahagun.2009.12">Flores Sahagun JE, Ortiz Soto JA, Mendez T, Cardenas Ochoa EC, Hernandez Flores G. <span><span class="ref-journal">Dermatology Online J. </span>2009;<span class="ref-vol">15</span>:12.</span> [Stevens Johsnon Syndrome and clindamycin-or chlorpheniramine-induced intrahepatic cholestatis] [<a href="/pubmed/19624990" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19624990</span></a>]<div><i>(48 year old woman developed jaundice at the end of an 8 day course of clindamycin and chlorpheniramine [bilirubin 3.5 mg/dL, ALT 1105 U/L, Alk P 444 U/L], with an accompanying rash that spread to mouth, palms and soles, responding to corticosteroids with rapid recovery within weeks).</i></div></div></li><li><div class="bk_ref" id="Clindamycin.REF.leitner.2010.3">Leitner JM, Graninger W, Thalhammer F. Hepatotoxicity of antibacterials: Pathomechanisms and clinical. <span><span class="ref-journal">Infection. </span>2010;<span class="ref-vol">38</span>:3–11.</span> [<a href="/pubmed/20107858" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20107858</span></a>]<div><i>(Review of frequency and cause of antibiotic induced liver injury, rates range from 0.2 [moxifloxacin] to 17 [amoxicillin/ clavulanate] per 100,000 prescriptions for different commonly implicated agents; mentions that clindamycin most frequently causes asymptomatic increases in ALT).</i></div></div></li><li><div class="bk_ref" id="Clindamycin.REF.reuben.2010.2065">Reuben A, Koch DG, Lee WM., Acute Liver Failure Study Group.  Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. <span><span class="ref-journal">Hepatology. </span>2010;<span class="ref-vol">52</span>:2065–76.</span> [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="/pubmed/20949552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div><i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, including 31 due to antibiotics, but none were attributed to clindamycin).</i></div></div></li><li><div class="bk_ref" id="Clindamycin.REF.bawany.2011.566">Bawany MZ, Bhutto B, Youssef WI, Nawras A, Sodeman T. Acute liver failure: an uncommon complication of commonly used medication. <span><span class="ref-journal">Am J Ther. </span>2011;<span class="ref-vol">20</span>:566–8.</span> [<a href="/pubmed/21642826" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21642826</span></a>]<div><i>(73 year old man developed jaundice 7 days after starting clindamycin [bilirubin 6.9 mg/dL, ALT 1076 U/L, Alk P 203 U/L, INR 2.1], liver tests improved on stopping, but patient developed respiratory followed by multiorgan failure and died soon thereafter).</i></div></div></li><li><div class="bk_ref" id="Clindamycin.REF.kwon.2012.268">Kwon H, Lee SH, Kim SE, Lee JH, Jee YK, Kang HR, Park BJ, et al.  Spontaneously reported hepatic adverse drug events in Korea: multicenter study. <span><span class="ref-journal">J Korean Med Sci. </span>2012;<span class="ref-vol">27</span>:268–73.</span> [<a href="/pmc/articles/PMC3286773/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3286773</span></a>] [<a href="/pubmed/22379337" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22379337</span></a>]<div><i>(Summary of 2 years of adverse event reporting in Korea; of 9360 reports, 567 were liver related, including 6 [1.1%] attributed to clindamycin).</i></div></div></li><li><div class="bk_ref" id="Clindamycin.REF.miller_quidley.2012.e387">Miller Quidley A, Bookstaver PB, Gainey AB, Gainey MD. Fatal clindamycin-induced drug rash with eosinophilia and systemic symptoms (DRESS) syndrome. <span><span class="ref-journal">Pharmacotherapy. </span>2012;<span class="ref-vol">32</span>:e387–92.</span> [<a href="/pubmed/23165860" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23165860</span></a>]<div><i>(63 year old woman developed nausea and a generalized erythematous rash 4 days after starting a course of clindamycin, with subsequent fever, eosinophilia [24%], lymphadenopathy, renal dysfunction, pancreatitis, and liver injury [bilirubin 4.3 mg/dL, ALT 67 U/L, Alk P 1010 U/L], with progressive multiorgan failure and death 16 days after presentation).</i></div></div></li><li><div class="bk_ref" id="Clindamycin.REF.bj_rnsson.2013.1419">Bj&#x000f6;rnsson ES, Bergmann OM, Bj&#x000f6;rnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. <span><span class="ref-journal">Gastroenterology. </span>2013;<span class="ref-vol">114</span>:1419–25.</span> [<a href="/pubmed/23419359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23419359</span></a>]<div><i>(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, of which none were attributed to clindamycin).</i></div></div></li><li><div class="bk_ref" id="Clindamycin.REF.hern_ndez.2014.231">Hern&#x000e1;ndez N, Bessone F, S&#x000e1;nchez A, di Pace M, Brahm J, Zapata R, A, Chirino R, et al.  Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. <span><span class="ref-journal">Ann Hepatol. </span>2014;<span class="ref-vol">13</span>:231–9.</span> [<a href="/pubmed/24552865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div><i>(Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, including 39 attributed to antimicrobial agents, but none to clindamycin).</i></div></div></li><li><div class="bk_ref" id="Clindamycin.REF.lim.2014.156389">Lim R, Choudry H, Conner K, Karnsakul W. A challenge for diagnosing acute liver injury with concomitant/sequential exposure to multiple drugs: can causality assessment scales be utilized to identify the offending drug? <span><span class="ref-journal">Case Rep Pediatr. </span>2014;<span class="ref-vol">2014</span>:156389. </span> [<a href="/pmc/articles/PMC4260426/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4260426</span></a>] [<a href="/pubmed/25506455" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25506455</span></a>]<div><i>(12 year old boy with severe cellulitis received amoxicillin, ceftriaxone, vanocmycin, ampicillin/sulbactam and clindamycin, whereupon he developed fever and jaundice [bilirubin 3.0 rising to 11.8 mg/dL, ALT 406 U/L, Alk P 404 U/L], resolving slowly and incompletely by 6 months; causality was complicated by polypharmacy, but authors attributed the injury to clindamycin).</i></div></div></li><li><div class="bk_ref" id="Clindamycin.REF.chalasani.2015.1340">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al. United States Drug Induced Liver Injury Network.  Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. <span><span class="ref-journal">Gastroenterology. </span>2015;<span class="ref-vol">148</span>:1340–52.e7.</span> [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 323 [36%] were attributed to antibiotics including two due to clindamycin; both with jaundice [initial bilirubin 3.4 and 6.4 mg/dL], one being hepatocellular, one mixed, both self limited).</i></div></div></li><li><div class="bk_ref" id="Clindamycin.REF.moole.2015.28746">Moole H, Ahmed Z, Saxena N, Puli SR, Dhillon S. Oral clindamycin causing acute cholestatic hepatitis without ductopenia: a brief review of idiosyncratic drug-induced liver injury and a case report. <span><span class="ref-journal">J Community Hosp Intern Med Perspect. </span>2015;<span class="ref-vol">5</span>:28746.</span> [<a href="/pmc/articles/PMC4612703/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4612703</span></a>] [<a href="/pubmed/26486111" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26486111</span></a>]<div><i>(75 year old woman developed jaundice while receiving a 10 day course of clindamycin [bilirubin 9.2 rising to 25 mg/dL, ALT 227 U/L, Alk P 296 U/L, INR 1.5 rising to 2.5], resolving within 4 weeks on prednisone therapy).</i></div></div></li><li><div class="bk_ref" id="Clindamycin.REF.okudo.2016.2724738">Okudo J, Anusim N. Hepatotoxicity due to clindamycin in combination with acetaminophen in a 62-year-old African American female: a case report and review of the literature. <span><span class="ref-journal">Case Reports Hepatol. </span>2016;<span class="ref-vol">2016</span>:2724738. </span> [<a href="/pmc/articles/PMC4947643/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4947643</span></a>] [<a href="/pubmed/27462474" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27462474</span></a>]<div><i>(62 year old woman developed liver test abnormalities 5 days after starting clindamycin [bilirubin normal, ALT 423, Alk P 321 U/L] and rose while it was continued [peak ALT 1927 U/L], with improvement on stopping).</i></div></div></li><li><div class="bk_ref" id="Clindamycin.REF.munz.2017.367">Munz M, Grummich H, Birkmann J, Wilhelm M, Holzgrabe U, S&#x000f6;rgel F. Severe drug-induced liver injury as an adverse drug event of antibiotics: a case report and review of the literature. <span><span class="ref-journal">Chemotherapy. </span>2017;<span class="ref-vol">62</span>:367–73.</span> [<a href="/pubmed/28934748" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28934748</span></a>]<div><i>(20 year old woman developed jaundice having recently received courses of amoxicillin, cefazolin and clindamycin [bilirubin 3.7 rising to 16.9 mg/dL, ALT 1219 U/L, Alk P 143 U/L, INR 1.57 rising to 2.6], with progressive liver failure but eventual spontaneous recovery with normal liver tests 2 months later).</i></div></div></li><li><div class="bk_ref" id="Clindamycin.REF.hoofnagle.2019.264">Hoofnagle JH, Bj&#x000f6;rnsson ES. Drug-induced liver injury - types and phenotypes. <span><span class="ref-journal">N Engl J Med. </span>2019;<span class="ref-vol">381</span>:264–73.</span> [<a href="/pubmed/31314970" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31314970</span></a>]<div><i>(Review of the clinical features, diagnosis, complications and pathogenesis of different forms of drug induced liver injury mentions that antibiotics are the most common medications causing liver injury, but they are also the most common class of medications approved for use in the US).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548292</span><span class="label">PMID: <a href="/pubmed/31643615" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643615</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Clemastine/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Clobazam/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548292&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548292/?report=reader">PubReader</a></li><li><a href="/books/NBK548292/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548292" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548292" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Clindamycin. [Updated 2019 Dec 16].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548292/pdf/Bookshelf_NBK548292.pdf">PDF version of this page</a> (148K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=clindamycin/AE+AND+Human%5BMH%5D+AND+(jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI+OR+hepatitis,+toxic%5BMH%5D)+AND+(%222009/09%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Clindamycin: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=clindamycin" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Clindamycin: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4854104" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4854104" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4854104" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643824" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Tobramycin</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Tobramycin<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/6589179" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Use of antibiotics in dental practice.</a><span class="source">[Dent Clin North Am. 1984]</span><div class="brieflinkpop offscreen_noflow">Use of antibiotics in dental practice.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Montgomery EH, Kroeger DC. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Dent Clin North Am. 1984 Jul; 28(3):433-53. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/2048603" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Antibiotic treatment of tuboovarian abscess: comparison of broad-spectrum beta-lactam agents versus clindamycin-containing regimens.</a><span class="source">[Am J Obstet Gynecol. 1991]</span><div class="brieflinkpop offscreen_noflow">Antibiotic treatment of tuboovarian abscess: comparison of broad-spectrum beta-lactam agents versus clindamycin-containing regimens.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Reed SD, Landers DV, Sweet RL. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am J Obstet Gynecol. 1991 Jun; 164(6 Pt 1):1556-61; discussion 1561-2. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/30745218" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Nationwide Organism Susceptibility Patterns to Common Preoperative Prophylactic Antibiotics: What Are We Covering?</a><span class="source">[J Arthroplasty. 2019]</span><div class="brieflinkpop offscreen_noflow">Nationwide Organism Susceptibility Patterns to Common Preoperative Prophylactic Antibiotics: What Are We Covering?<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Nodzo SR, Boyle KK, Frisch NB. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Arthroplasty. 2019 Jul; 34(7S):S302-S306. Epub 2019 Jan 17.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31644016" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Gentamicin</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Gentamicin<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643615" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643615" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=60467cbaa19b7255ae01c88e">Clindamycin - LiverTox</a><div class="ralinkpop offscreen_noflow">Clindamycin - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T14:36:26-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal106&amp;ncbi_phid=CE8D132404663D910000000005DD01B8&amp;ncbi_session=CE8D13240467CB91_1501SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548292%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548292&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548292/&amp;ncbi_pagename=Clindamycin - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8D13240467CB91_1501SID /projects/books/PBooks@9.2 portal106 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>